In Brief: Roche European PCR patent:
This article was originally published in The Gray Sheet
Executive Summary
Roche European PCR patent: Hoffman-La Roche expects to receive a European patent within the next six months covering enzymes used in the company's polymerase chain reaction gene amplification technology. At a Nov. 6 hearing, the European Patent Office accepted Roche's claims for native and recombinant thermostable DNA polymerases, clearing the way for a patent covering "thermostable enzymes having DNA polymerase activity from any species of bacteria such as Taq DNA polymerase from Thermus aquaticus," the company says...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.